Format

Send to

Choose Destination
J Infect Dis. 2018 Apr 11;217(9):1417-1420. doi: 10.1093/infdis/jiy037.

Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome.

Author information

1
Department of Preventive Medicine, Armed Forces Medical Command, Seongnam.
2
Department of Medicine, Third Republic of Korea Army Command, Yongin.
3
Division of Infectious Diseases, Department of Medicine, Armed Forces Capital Hospital, Seongnam.
4
Department of Microbiology, Korea University College of Medicine, Seoul, Republic of Korea.

Abstract

As there is no effective treatment against hemorrhagic fever with renal syndrome (HFRS), the development of effective vaccine is important. An inactivated hantavirus vaccine (IHV) has been used in Korea, but there has been controversy regarding its effectiveness. We conducted a case-control study to evaluate the vaccine effectiveness (VE) of IHV against HFRS in the Korean military. Unadjusted and adjusted VEs of IHV were 59.1% and 58.9%, respectively. VE was higher in divisions with high incidence of HFRS (unadjusted VE, 71.4%; adjusted VE, 78.7%). Our study demonstrated the moderate effectiveness of IHV in high-risk populations residing in endemic area.

PMID:
29373686
DOI:
10.1093/infdis/jiy037

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center